semaglutide cardiovascular The weight-loss drug Wegovy lowered heart attack risk in a large trial ACC 2025: Oral Semaglutide Reduces

That is only a two-day gap

[16] [17] Whether these risks apply to retatrutide specifically is not yet established, as the full long-term safety profile remains unknown pending Phase 3 data

GLP-1s are most well studied for weight loss (obesity) and blood sugar control (type 2 diabetes)

GLP-1based therapies share several common adverse effects and carry some rare but important risks

Vomiting, throwing up stomach contents, is typically attributed to a gallbladder attack, an unofficial term for when symptoms of gallbladder issues flare up suddenly

D12492i) for 20 weeks before ICV cannulation surgery and were 6 months old at the start of the study